PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include regular earnings coverage and provide timely updates to company product forecasts.
Publisher: Datamonitor Healthcare
Published: 21 July 2020
Number of pages:36
PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29.
Overview – Boehringer Ingelheim will see near-term growth, but will see long-term revenue declines because of fewer NMEs in its late-stage pipeline compared to its peers.
Key themes –  Upcoming label expansions for Jardiance should help to sustain recent robust revenue trends  Ofev should see continued growth in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease associated with systemic sclerosis (SSc-ILD)  Boehringer Ingelheim will see royalties from Skyrizi, which has already become a blockbuster product for AbbVie.
Model updates (20 May 2020)
Jardiance forecast adjusted higher
Glyxambi forecast removed due to Boehringer not providing brand-level revenue performance
Stiolto forecast removed due to Boehringer not providing brand-level revenue performance.
Model updates (6 August 2019)
Ofev forecast adjusted higher due to market share gains within IPF
Jardiance forecast adjusted higher due to strong growth.
Table of Contents
Key Drug & Company Information
Prescription Pharmaceuticals Sales Outlook
Branded Drug Outlook
Therapy Area Outlook
Regional Sales Outlook
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.